A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency
Skoromets, A.A.; Tanashian, M.M.; Chukanova, E.I.; Petrova, E.A.; Spirin, N.N.; Nikonov, A.A.; Peverennova, I.E.; Levin, I.I.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 109(5 Suppl. 2): 44-48
2009
ISSN/ISBN: 1997-7298 PMID: 19894300 Document Number: 630455
An assessment of the complex multicenter prospective non-comparative program aimed at studying of efficacy and safety of a new scheme of therapy with cavinton in patients with chronic cerebrovascular insufficiency has been conducted. One hundred and forty-nine patients (46 male, 113 female), aged from 35 to 65 years, have been examined. The treatment started from intravenous infusions of the drug during 7 days as follows: 20, 30, 40, 50, 50, 50 and 50 mg of cavinton solution diluted in 500 ml of physiologic solution with the following peroral taking of cavinton forte in dose 10 mg 3 times daily during 11 weeks. Efficacy of drug was primarily assessed with MMSE and then by SF-36 and CGIC-PGIC. There were significant differences in scores on MMSE and SF-36 before and after treatment and on CGIC-PGIC on the 8th and 90th days of the study. The parenteral and peroral use of cavinton is well-tolerated and has a favorable safety profile.